Under construction – not a live service
Sign in
Active, not recruitingPhase 2

A Trial of Lu AG13909 in Adult Participants With Cushing's Disease

Key facts

Who runs it
H. Lundbeck A/S
Where
Ann Arbor and St Louis, United StatesSee the 2 sitesAlso in 8 other countries, 26 sites
Status
Active, not recruiting
Phase
Phase 2
People taking part
16 people enrolled
Started
19 Jun 2024
Expected to end
31 Oct 2027
Type of study
Interventional
Treatments tested
  • Lu AG13909
Record updated
16 October 2026

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • The participant is a man or woman with a confirmed diagnosis of adrenocorticotropic hormone (ACTH) driven CD of pituitary source as per current guidelines
  • Morning plasma ACTH levels > lower limit of normal (LLN) and
  • Evidence of a pituitary origin of the excess ACTH:; Either MRI confirmation of pituitary adenoma >6 millimeters (mm), or ii. inferior petrosal sinus gradient >2, or iii. histopathology confirmation of ACTH-secreting tumour
  • The participant has a 24-hour UFC >1.5 × ULN (the mean of ≥3 days of 24-hour urine collection)
  • Apart from CD and associated well-controlled comorbidities (for example, diabetes mellitus and hypertension), the participant is generally healthy in the opinion of the investigator and based on medical history, physical examination, vital signs, electrocardiogram (ECG), and the results of the safety laboratory tests
  • For participants on medical treatment for hypercortisolism due to CD, pre-defined washout periods must be completed prior to the Baseline efficacy assessments

Who cannot take part

  • The participant has immediate need for pituitary surgery within 6 months from screening in the opinion of the investigator
  • The participant had pituitary surgery <3 month prior to screening
  • The participant had pituitary radiotherapy within the last 10 years; Other protocol-defined criteria apply
  • The participant has a history of known hypersensitivity or intolerance to Lu AG13909 or its excipients
  • The participant has severe CD per investigator judgement; among others, this could be participants with:; poorly controlled hypertension ii. poorly controlled diabetes mellitus iii. severe psychiatric illness iv. compression of the optic chiasm causing any visual field defect or risk thereof v. very high risk of thromboembolic events
  • The participant has a clinically significant abnormal laboratory value, ECG parameter, vital signs value, or other safety findings at the Screening Visit that indicate a potential risk to the participant's safety if enrolled, in the opinion of the investigator
  • The participant is pregnant, breastfeeding, intends to become pregnant, or is of child-bearing potential and not willing to use adequate contraceptive methods

Where in United States

Also in 8 other countries, 26 sites

  • University of Michigan Health-A. Alfred Taubman Health Care CenterAnn Arbor, United StatesNo longer taking part
  • Washington University School of Medicine in St. LouisSt Louis, United StatesNo longer taking part

About the trial

What the trial wants to find out

This trial will evaluate the effects of Lu AG13909 in adult participants with Cushing's disease (CD). CD is a rare and serious disorder where the body makes too much of a hormone called cortisol. The main goals of this trial are to learn about

Read full original descriptionShow less

1. the effect of Lu AG13909 on cortisol levels. 2. the safety and tolerability of Lu AG13909. 3. the pharmacokinetic parameters of Lu AG13909 (how the drug is absorbed, distributed, and processed by the body).

The group in the trial

  • Lu AG13909Treatment being tested

    Participants will first receive Lu AG13909 IV per predefined dosing schedule. Participants will then receive Lu AG13909 SC per predefined dosing schedule.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Phase II, Multi-site, Open-label, Dose-titration Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AG13909 in Adults With Cushing's Disease
Record updated
16 October 2026